Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 28, 2003

View Archived Issues

NCI to evaluate TNFerade for rectal cancer

TaiGen receives funding for SARS drug development efforts

Anti-TNF-alpha antisense oligonucleotide effective and safe in rheumatoid arthritis

Polyphenon E (EGCg) improves preaged and damaged facial skin

Alefacept therapy beneficial in the treatment of psoriasis

CTLA-4Ig reported to improve quality of life and physical function in rheumatoid arthritis

Statins in the prevention of atherosclerosis caused by SLE

Novel Kv1.3 channel blockers with utility in multiple sclerosis and other immune disorders

Nonpeptide GnRH antagonists and their use claimed by Ferring

Novel elastase inhibitors prepared and tested by Dainippon scientists

Meiji Milk and Kitasato Institute researchers discover new agents for flu

Meiji Milk patent describes a cholesterol-lowering peptide

Two series of MEK inhibitors identified at Array BioPharma

New antifungal agents, their isolation and biological evaluation claimed by Sankyo

Kyowa Hakko presents urethra-selective agents for urinary incontinence therapy

Safety and pharmacokinetics of single-dose MEDI-522 in rheumatoid arthritis

LibiGel meets endpoints in interim analysis of phase II trial for FSD

Aventis submits complete response for Ketek

Shareholder approval for Cell Therapeutics/Novuspharma merger

FDA schedules advisory committee review date for Ranexa

IBC enters research collaboration with Schering for cancer

Stalevo approved for Parkinson's disease in E.U.

Teva to commercialize OrCel in Israel

Studies support antiinflammatory, osteogenic and muscle-healing properties of BPC-157

OSI-7904L evaluated in new phase II study for gastric cancer

TA-CD advances into phase IIb for cocaine addiction

Antitumor agent CCI-779 as potential therapy for RA patients

Preclinical efficacy, safety and PK data discussed for IDN-6556 at AASLD meeting

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for June 18, 2025.
An early stage 85% remissions rate in AML drives Aptevo’s stock surge
BioWorld
An 85% remissions rate was found in updated results from Aptevo Therapeutics Inc.’s ongoing phase Ib/II Ranier study of mipletamig in one of the toughest blood...
BIO 2025: Makary lays out FDA’s path, launches pilot review program
BioWorld
On the same day that FDA Commissioner Martin Makary spoke in a fireside chat during the 2025 Biotechnology Innovation Organization’s International Convention, the...
Alphadesign: AI creating proteins from scratch
BioWorld Science
The Alphafold machine learning system for predicting a protein’s structure from its amino acid sequence has been adapted to make it possible to design de novo...